ClinicalTrials.gg
RecruitingNCT07024160Updated Jul 3, 2025

Phase I Study of MT1011 Injection in Healthy Subjects

A Phase 1 interventional study of MT1011 and Placebo in Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.

02

Conditions studied

  • Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
03

In context

Lead sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects (with at least 1/4 being either female or male), aged 18 to 45 years (inclusive) at screening;
  2. Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females at screening, with a [BMI = weight (kg) / height² (m²)] within the range of 18.5 to 26.0 kg/m² (inclusive);
  3. Subjects must provide for this study prior to participation and voluntarily sign a written informed consent form;
  4. Subjects must be able to maintain good communication with the investigators.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with abnormal and findings in vital signs, physical examination, laboratory tests (blood routine, urinalysis, blood biochemistry, coagulation function), abdominal ultrasound, or chest X-ray as determined by the investigator;
  2. Women who are pregnant or breastfeeding, or female subjects with positive pregnancy tests; Subjects (or their partners) planning pregnancy, or planning to donate sperm/ova during the study or within
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    MT1011

    Interventional: The SAD study involves single administration of MT1011

    Drug: MT1011

  • Placebo comparator
    Placebo

    Placebo: The SAD study involves single administration of Placebo.

    Drug: Placebo

Interventions

  • DrugMT1011

    MT1011 is a novel synthetic small molecule anticoagulant reversal agent for reversing anticoagulant effects including factor IIa and Xa inhibitors.

  • DrugPlacebo

    This intervention contains no active ingredients

06

What researchers measure

Primary outcomes

  1. Incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events)and treatment-related adverse events (TEAEs).

    The occurrence of all adverse events (AEs), serious adverse events (SAEs)

    Time frame: up to Day 14

Secondary outcomes

  1. Cmax of MT1011

    Cmax - Maximum plasma concentration

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.

  2. Tmax of MT1011

    Tmax - Time to reach Cmax

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.

  3. T1/2 of MT1011

    t1/2 - Elimination half-life

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.

  4. AUC0-tau of MT1011

    AUC0-tau - Area under the plasma concentration-time curve during one dosing interval

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.

  5. AUC0-t of MT1011

    AUC0-t - Area under the plasma concentration-time curve from time zero to the last measurable concentration

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 5min,15min,0.5,1, 2, 4, 8, 12, 24, 48 hours post-dose.

  6. Whole blood clotting time

    Whole blood clotting time

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.

  7. Activated partial thromboplastin time

    Activated partial thromboplastin time

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.

  8. Prothrombin time

    Prothrombin time

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.

  9. fibrinogen

    fibrinogen

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.

  10. International normalized ratios

    International normalized ratios

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.

  11. Thrombin time

    Thrombin time

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.

  12. Factor Xa activity

    Factor Xa activity

    Time frame: Within 1 hour before dosing on Day 1 (D1), and at 15min, 2, 24 hours post-dose.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2026
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07024160
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jun 25, 2025
Primary completion
Apr 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Jul 3, 2025

Study contacts

Xiao Hua Hao, Ph.D. in Medicine
Contact
xiaohualuck@sina.com
010-63926883

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion